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Prescription Opioid Use and Risk for Major Depressive Disorder
and Anxiety and Stress-Related Disorders
A Multivariable Mendelian Randomization Analysis
Daniel B. Rosoff, AB, ScB; George Davey Smith, MD, DSc; Falk W. Lohoff, MD
IMPORTANCE Growing evidence suggests that prescription opioid use affects depression and
anxiety disorders; however, observational studies are subject to confounding, making causal
inference and determining the direction of these associations difficult.
OBJECTIVE To investigate the potential bidirectional associations between the genetic liability
for prescription opioid and other nonopioid pain medications and both major depressive
disorder (MDD) and anxiety and stress-related disorders (ASRD) using genetically based
methods.
DESIGN, SETTING, AND PARTICIPANTS We performed 2-sample mendelian randomization (MR)
using summary statistics from genome-wide association studies (GWAS) to assess potential
associations of self-reported prescription opioid and nonopioid analgesics, including
nonsteroidal anti-inflammatories (NSAIDs) and acetaminophen-like derivatives use with MDD
and ASRD. The GWAS data were derived from participants of predominantly European
ancestry included in observational cohorts. Data were analyzed February 20, 2020, to May 4,
2020.
MAIN OUTCOMES AND MEASURES Major depressive disorder, ASRD, and self-reported pain
medications (opioids, NSAIDs, anilides, and salicylic acid).
RESULTS The GWAS data were derived from participants of predominantly European ancestry
included in the population-based UK Biobank and Lundbeck Foundation Initiative for
Integrative Psychiatric Research studies: approximately 54% of the initial UK Biobank sample
and 55.6% of the Lundbeck Foundation Initiative for Integrative Psychiatric Research sample
selected for the ASRD GWAS were women. In a combined sample size of 737 473 study
participants, single-variable MR showed that genetic liability for increased prescription opioid
use was associated with increased risk of both MDD (odds ratio [OR] per unit increase in log
odds opioid use, 1.14; 95% CI, 1.06-1.22; P < .001) and ASRD (OR, 1.24; 95% CI, 1.07-1.44;
P = .004). Using multivariable MR, these opioid use estimates remained after accounting for
other nonopioid pain medications (MDD OR, 1.14; 95% CI, 1.04-1.25; P = .005; ASRD OR, 1.30;
95% CI, 1.08-1.46; P = .006), and in separate models, accounting for comorbid pain
conditions. Bidirectional analyses showed that genetic liability for MDD but not ASRD was
associated with increased prescription opioid use risk (OR, 1.18; 95% CI, 1.08-1.30; P < .001).
These estimates were generally consistent across single-variable and multivariable inverse
variance–weighted (MV-IVW) and MR-Egger sensitivity analyses. Pleiotropy-robust methods
did not indicate bias in any MV-IVW estimates.
CONCLUSIONS AND RELEVANCE The findings of this mendelian randomization analysis suggest
evidence for potential causal associations between the genetic liability for increased
prescription opioid use and the risk for MDD and ASRD. While replication studies are
necessary, these findings may inform prevention and intervention strategies directed toward
the opioid epidemic and depression.
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T he United States is in the middle of an opioid epidemic,1with an approximately 5-fold increase in opioid pre-scription use over the past 20 years resulting in large in-
creases in opioid misuse.2 Opioid-related deaths are rapidly in-
creasing, and approximately 68% of the 702 000 drug overdose
deaths in the United States from 2013 to 2017 involved
opioids.3,4 It is also reported that prescription opioids (vs il-
licit opioids) are the first opioids to be misused,5 with almost
30% of patients prescribed opioids for chronic pain misusing
them6 and about 12% developing opioid use disorder (OUD).6
Informed prescribing practices require comprehensive un-
derstanding of the treatment’s risks and benefits, and while
opioids alleviate pain, chronic use is associated with numer-
ous adverse effects, including immunosuppression, natural re-
ward processes dysregulation, and neurohormonal deficits.7,8
Observational studies have also found opioid use to be highly
comorbid with both major depressive disorder (MDD) and anxi-
ety and stress-related disorders (ASRD).9-12 It is estimated that
the approximately 7.8 million adults with psychiatric disor-
ders (primarily MDD and ASRD) receive more than half of the
almost 200 million yearly opioid prescriptions.10 Compared
with other patient populations, individuals with psychiatric
disorders are also more likely to report long-term opioid use.13-15
Because MDD and ASRD are leading global causes of dis-
ability and death,16,17 elucidating the direction and poten-
tially causal effect of these associations would be useful to in-
form prevention strategies. Literature suggests prescription
opioid use increases MDD risk,18-21 and while observational
findings suggest a potential association between prescrip-
tion opioid use, MDD, and ASRD, observational data are sub-
ject to confounding and reverse causation, making causal in-
ference difficult.22,23 Therefore it remains to be elucidated
whether MDD is a cause or consequence of prescription opi-
oid use.18 While prospective randomized clinical trials (RCTs)
are the criterion standard of causal inference,24 performing
RCTs to evaluate the effects of prescription opioid use or other
nonopioid pain medications is often complicated by preexist-
ing psychiatric comorbidities.
Mendelian randomization (MR), which uses single-
nucleotide variants (SNVs) as unconfounded proxies for ex-
posures to estimate their effect on outcomes of interest, mini-
mizes the bias affecting observational epidemiologic
studies.23,25-27 Conceptually, MR has analogies with RCTs, with
randomization occurring at meiosis,23,26 and is an important
strategy for strengthening causal inference when RCTs are im-
practical or unethical.23 Given the public health importance
of assessing the possible bidirectional associations between
prescription opioid use and neuropsychiatric disorders, gain-
ing causal inference into these associations would be impor-
tant to aid prevention strategies.
In the absence of RCTs, we used a 2-sample MR study de-
sign of summary-level data on self-reported prescription opi-
oid use in the UK Biobank (UKB),28 the largest genome-wide
association study (GWAS) to date on MDD29 and the largest
GWAS to date on ASRD,30 to conduct bidirectional MR analy-
ses investigating potential causal associations between the ge-
netic liability for opioid pain medications and MDD and ASRD.
Given prescription opioid medications are given for pain, and
pain increases the risk for both MDD and ASRD,31,32 we aimed
to provide context to our primary prescription opioid analy-
sis by including other common pain medications, including ani-
lides, salicylic acid and derivatives, and nonsteroidal anti-
inflammatory drugs (NSAIDs) and chronic pain conditions to
the study. We also leveraged multivariable MR (MVMR) meth-
ods developed in 201933 to account for potential confound-
ing owing to these pain medications and chronic pain condi-
tions that may affect the use of prescription opioid analgesics
and the risk for these psychiatric disorders.
Methods
Study Design and Data Sources
A detailed description of the methods used in this study is pro-
vided in the eMethods in the Supplement. We used publicly
available summary statistics from 3 GWAS sources of predomi-
nantly European ancestry (Figure 1; eTable 1 in the Supple-
ment). All studies have existing ethical permissions from their
respective institutional review boards and include partici-
pant written informed consent and rigorous quality control.
Because all analyses herein are based on publicly available sum-
mary data, no ethical approval from an institutional review
board was required for this study. Data for this study were ana-
lyzed from February 20, 2020, to May 4, 2020.
Data Sets
We used summary statistics from the first medication use case-
control GWAS conducted among UKB study participants to gen-
erate genetic instruments for opioid and nonopioid pain
medications.28 Pain medication categories were classified by
active ingredient using the Anatomical Therapeutic Chemi-
cal Classification System and then assigned to 23 categories
by active ingredient, including opioids (eg, morphine, oxyco-
done, codeine, fentanyl, pethidine, and tramadol), NSAIDs, ani-
lides, and salicylic acid products (eTable 2 in the Supple-
ment). Approximately 54% of UKB study participants are
women, and the mean (SD) age of UKB study participants on
the first visit UKB assessment was 56.5 (8.1) years.28 We also
used summary statistics from MRC-IEU UKB GWASs34 for 6
PHEnome Scan Analysis Tool (PHESANT)35 phenotypes re-
lated to site-specific (back, knee, hip, neck/shoulder, head-
ache, and abdominal/stomach) pain occurring for more than
3 months.
Key Points
Question Does prescription opioid medication have a potentially
causal role in the risk for depression and anxiety disorder?
Findings In this 2-sample mendelian randomization study using
genetic instruments for common pain medications, the genetic
liability for prescription opioid use was associated with increased
risk for major depression.
Meaning While further work is needed, this genetics-based study
supports conventional observational literature suggesting
prescription opioid use increases the risk for depression.
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We used summary statistics from the largest publicly avail-
able GWASs for our MDD and ASRD gene associations.29,30 The
MDD cases were required to meet international consensus cri-
teria (DSM-IV, International Classification of Diseases, Ninth Re-
vision, or International Statistical Classification of Diseases and
Related Health Problems, Tenth Revision) for a lifetime diag-
nosis of MDD (45 591 cases and 97 674 controls).29 The MDD
GWAS meta-analysis29 incorporated 29 cohorts. Cohorts had
a wide range of ages (18 to >80 years), and approximately 56.0%
of the participants were women.29 The ASRD cases and con-
trols (12 665 cases and 19 220 controls) were selected from the
Danish Lundbeck Foundation Initiative for Integrative Psychi-
atric Research (iPSYCH) cohort, a representative sample from
the population of Denmark born between May 1, 1981, and De-
cember 31, 2005.30 Approximately 55.6% of ASRD sample par-
ticipants were women. The ASRD cases were assigned by a
psychiatrist during routine clinical care according to the in-
ternational Statistical Classification of Diseases and Related
Health Problems (10th Revision).30 Both MDD and ASRD co-
hort participants were of European ancestry, and all GWASs in-
cluded age and sex as covariates in the association analysis;
population stratification is taken into account in the princi-
pal components analysis.28-30
Sample Independence
Participant overlap in samples used to estimate genetic asso-
ciations between exposures and outcomes can increase weak
instrument bias in MR analyses.36,37 We avoided overlap in our
analyses of pain medication use on MDD and ASRD: we used
meta-analytic results for MDD that excluded the UKB cohort
(n = 29 740). To improve precision for the bidirectional analy-
ses of MDD on pain medication use, we used meta-analytic re-
sults for MDD including additional cohorts from 23andMe
(n = 307 354) and UKB (overall n = 480 359). Hence, sample
overlap (for bidirectional analyses) was minimal (6.2%), and
because MDD instrument strength was considered strong
(F statistic of approximately 32, see subsequent text), consid-
erable weak instrument bias is not expected.37
Statistical Analysis
All analyses were performed using the TwoSampleMR and
MendelianRandomization R packages (The R Foundation). We
selected all relevant SNVs identified in each GWASs as having
reached selection threshold P less than 5 × 10−6 and being un-
correlated (10 000 kilobase pairs apart and R2 ≤.001). We ob-
tained SNV effects and corresponding standard errors from the
exposure and outcome GWASs.38 We harmonized exposure and
outcome data, removed palindromic SNVs with intermediate
allele frequencies, and estimated the F parameter to evaluate
instrument strength.37 We applied Steiger filtering to the har-
monized data to identify and remove those SNVs exhibiting
reverse causation by the test metric. The observed variance of
the outcome exceeded the observed variance of the exposure
explained by the SNVs (eTables 3-8 in the Supplement: har-
monized data sets).39
For single-variable MR analysis, we used inverse variance–
weighted (IVW) MR as the primary method. However, be-
cause this method gives consistent estimates only if all












Primary exposure (UKB, European)
(Wu et al28)
• Prescription opioid use (n ≤ 78 808)
Secondary exposures (UKB, European)
(Wu et al28)
• Anilide use (n ≤ 179 870)
• NSAID use (n ≤ 164 520)
• Salicylic acid use (n ≤ 112 010)
• Major depression/major depressive
disorder (PGC, European)
(Wray et al29)
(cases = 45 591; controls = 97 674)
• Anxiety and stress-related disorder
(iPSYCH, European)
(Meier et al30 )
(cases = 12 665; controls = 19 225)
Site-specific chronic pain lasting
≥3 mo (UKB, European)
(Elsworth et al34)
• Back (n ≤ 117 404)
• Neck/shoulder (n ≤ 105 396)
• Hip (n ≤ 51 516)
• Headache (n ≤ 91 269)
• Knees (n ≤ 97 889)
• Abdominal/stomach (n ≤ 38 911)
All summary-level genetic associations were derived from cohorts of European
ancestry. Consortium, study cohort, and author information of original
genome-wide association study for each exposure, confounder, and outcome
included in the study are in parentheses. B2 is the association of interest
(prescription opioid use on major depressive disorder [MDD] and anxiety and
stress-related disorder [ASRD] risk), estimated by B2 = B1 / B3. B1 and B3 are the
estimated direct association of the genetic variants on the exposure (ie,
prescription opioid use) and the outcomes (ie, MDD and ASRD), respectively.
iPSYCH indicates The Lundbeck Foundation Initiative for Integrative Psychiatric
Research; IVW, inverse variance–weighted MR; MRC-IEU, Medical Research
Center-Integrative Epidemiology Center (UK Bristol); NSAID, nonsteroidal
anti-inflammatory or antirheumatic drugs; PGC, Psychiatric Genomics
Consortium; SNV, single-nucleotide variant; UKB, UK Biobank.
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genetic variants are valid instrumental variables (IVs), we con-
sidered complementary MR-Egger and weighted median-
based regression methods, which make different IV assump-
tions, as a sensitivity analysis to address the question of
robustness of our IVW estimate.23,38,40 The MR-Egger regres-
sion gives consistent estimates when 100% of genetic vari-
ants are invalid IVs; weighted median requires 50% of the
weight to come from valid IVs. However, regarding effi-
ciency, weighted median estimates generally are nearly as pre-
cise as IVW estimates; both are substantially more precise than
MR-Egger estimates, with MR-Egger regression estimates par-
ticularly imprecise if all IVs have similar magnitudes of asso-
ciation with the exposure.41 We used the MR-Egger intercept
test,42 Cochran Q heterogeneity test,43 and MR pleiotropy re-
sidual sum and outlier (MR-PRESSO) test44 to evaluate poten-
tial IV violations. We also performed leave-one-out analyses
to detect high influence points.39
For MVMR analyses, we constructed instruments using
SNVs in each of the GWASs meeting our single-variable MR
selection criteria, described previously. We used the MVMR
extension of the inverse-variance weighted MR method36
and MR-Egger method to correct for both measured and
unmeasured pleiotropy.45 We combined the SNVs from the
relevant GWASs: prescription opioid plus nonprescription
pain medications; prescription opioid plus each of the
chronic pain conditions; and the bidirectional MDD plus
ASRD instrument. We removed duplicate and correlated
SNVs (within 10 000 kilobase pairs; R2 ≥0.001), then
extracted the SNV effects and corresponding standard
e r r o r s f r o m t h e e x p o s u r e s a n d o u t c o m e G WA S s
(eTables 9-14 in the Supplement: harmonized data sets).
The MR estimates are reported as odds ratios (ORs)
interpreted as MDD or ASRD risk per unit increase in log
odds of the opioid or nonopioid medication use (or alterna-
tively, for bidirectional results, the medication use risk per
unit increase in log odds of MDD or ASRD). We report confi-
dence intervals for the main results. We index the strength
of evidence against the null hypotheses (no association) by
the exact P value. While we caution against interpreting
study findings solely on the basis of a P-value threshold,46
we use a 2-sided α of .00625 based on testing 4 pain medi-
cations categories against 2 psychiatric outcomes as a heu-
ristic allowing for follow-up of a plausible number of find-
ings. In assessing consistency and robustness, we looked for
estimates substantially agreeing in direction and magnitude
(overlapping confidence intervals) across complementary
MR methods.
Results
Single-variable conventional MR analysis showed only
genetically determined prescription opioid use having an
effect estimate consistent with increased risk for both MDD
(IVW OR, 1.14; 95% CI, 1.06-1.22; P < .001) and ASRD (IVW
OR, 1.24; 95% CI, 1.07-1.44; P = .004) (Table 1 and Figure 2;
eTables 15-18 in the Supplement). These estimates were
broadly consistent with estimates from the weighted
median and MR-Egger sensitivity analyses; the MR-Egger
estimates were substantially less precise (MDD WMOR, 1.18;
95% CI, 1.07-1.30; P < .001; ASRD WM OR, 1.22; 95% CI,
1.00-1.49; P = .05; MDD MR-Egger OR, 1.17; 95% CI, 0.92-
1.47; P = .21; ASRD MR Egger OR, 1.26; 95%CI, 0.78-2.02;
P = .36). The MR-Egger intercept analysis did not indicate
horizontal pleiotropy. Conventional IVW leave-one-out
analysis did not identify any high leverage points with high
Table 1. Single-Variable MR Results of Prescription Opioid and Nonopioid Pain Medication Use on Risk of MDD and ASRDa,b
Exposure Method
MDD ASRD
N SNV OR (95% CI) P value N SNV OR (95% CI) P value
Opioid use
IVW 26 1.14 (1.06-1.22) <.001 23 1.24 (1.07-1.44) .004
Weighted median 26 1.18 (1.07-1.30) <.001 23 1.22 (1.00-1.49) .05
MR Egger 26 1.17 (0.92-1.47) .21 23 1.26 (0.78-2.02) .36
Salicylic acid use
IVW 27 1.07 (0.98-1.18) .15 21 1.18 (1.00-1.40) .05
Weighted median 27 1.04 (0.92-1.18) .52 21 1.14 (0.91-1.44) .25
MR Egger 27 0.83 (0.66-1.04) .12 21 0.92 (0.56-1.52) .75
Anilide use
IVW 29 1.14 (1.01-1.27) .03 34 1.01 (0.82-1.25) .93
Weighted median 29 1.14 (0.97-1.34) .10 34 0.96 (0.70-1.30) .77
MR Egger 29 1.05 (0.67-1.64) .82 34 0.85 (0.37-1.94) .70
NSAID use
IVW 29 1.12 (1.02-1.23) .02 29 1.29 (1.06-1.56) .01
Weighted median 29 1.20 (1.05-1.37) .008 29 1.13 (0.86-1.47) .38
MR Egger 29 1.11 (0.78-1.58) .56 29 1.18 (0.52-2.68) .70
Abbreviations: ASRD, anxiety and stress-related disorder; GWAS, genome-wide
association studies; IVW, inverse variance weighted; MDD, major depression or
major depressive disorder (depending on study); MR, mendelian
randomization; N SNVs, number of genetic instruments; NSAID, nonsteroidal
anti-inflammatory drug; OR, odds ratio; SNV, single-nucleotide variant; SVMR,
single-variable mendelian randomization.
a Results from 2-sample SVMR analysis; main analysis method: outliers
identified by MR PRESSO tool, removed; estimated associations reported as
OR of outcome per unit increase in log odds of pain medication use.
b Genetic instruments selected from opioid and nonopioid pain medication use
GWASs, selection threshold P less than 5 × 10−6, pruned at linkage
disequilibrium R2 less than .001 (10 000 kilobase pair window); N SNV differs
across outcomes depending on number of genetic instruments found in
outcome GWASs.
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Figure 2. Scatterplot and Leave-One-Out Analysis of Associations of Genetic Risk of Prescription Opioid Use

















SNV effect on opioid use
Scatterplot of risk of MDDA
0.300 0.05 0.15 0.250.10 0.20
OR (95% CI)
Leave-one-out analysis for opioid use on MDDB






















SNV effect on opioid use
Scatterplot of risk of ASRDC
0.300 0.05 0.15 0.250.10 0.20




























































Leave-one-out analysis for opioid use on ASRDD
1.00 1.25 1.601.05 1.45
































































Scatterplot of independent instrument single-nucleotide variant (SNV)
exposure effects vs outcome effects from 2 independent samples augmented
by the standard error of these effects on the vertical and horizontal sides (for
presentation, alleles are coded so that all SNV exposure effects are positive).
Solid lines are the regression slopes fitted by the primary inverse
variance–weighted (IVW) and complementary mendelian randomization (MR)
methods: slopes fitted by IVW MR method were very similar in direction and
magnitude to slopes fitted by MR-Egger and weighted median methods for
both risk of major depressive disorder (MDD) (A) and risk of anxiety and
stress-related disorders (ASRD) (C). In leave-one-out sensitivity analyses, IVW
MR was performed leaving out each SNV in turn to identify whether a single
SNV may be driving the association, with results illustrated in plots showing that
no single SNV was driving the association between genetic risk of prescription
opioid use and MDD (B) or ASRD (D), respectively: the relevant comparisons
would be between the overall IVW MR interval estimate ("ALL") vs each
leave-one-out MR interval estimate, for MDD (B) and ASRD (D), respectively.
Interval estimates are expressed as odds ratios (ORs) of risk of MDD or ASRD
per unit increase in log odds of prescription opioid use. Heterogeneity tests did
not indicate heterogeneity in the IVW estimates of prescription opioid use on
either risk of MDD or ASRD; pleiotropy robust methods indicated no bias in the
IVW estimates (eTable 15 in the Supplement).
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influence (Figure 2; eFigures 1-5 in the Supplement). The F
statistics for the genetic instruments were consistent with
an absence of weak instrument bias.
In MVMR, assessing the genetic liabilities for prescrip-
tion opioid and nonopioid pain medications use jointly,
opioid use retained a robust relationship with both MDD
(IVW OR, 1.14; 95% CI, 1.04-1.25; P = .005) and ASRD (IVW
OR, 1.30; 95% CI, 1.08-1.56; P = .006) (Table 2; eTable 19 in
the Supplement). These estimates were broadly consistent
with estimates from the MVMR-Egger sensitivity analyses,
although the MVMR-Egger estimates were again substan-
tially less precise for MDD (OR, 1.13; 95% CI, 1.02-1.26;
P = .02), and similarly, ASRD (OR, 1.18; 95% CI, 0.95-1.46;
P = .13). The MR-Egger intercept analysis again did not indi-
cate horizontal pleiotropy. In additional MVMR analyses,
assessing the genetic liability for prescription opioid use
jointly with site-specific pain, opioid use retained that asso-
ciation with both MDD and ASRD (eg, controlling for back
pain: MDD IVW OR, 1.12; 95% CI, 1.05-1.21; P = .001; ASRD
OR, 1.26; 95% CI, 1.09-1.45; P = .002), again, the MVMR-
Egger estimates consistent but substantially less precise
(MDD MR-Egger OR, 1.12; 95% CI, 0.95-1.30; P = .19; ASRD
MR-Egger OR, 1.27; 95% CI, 0.90-1.80; P = .18). The
MR-Egger intercept analysis again did not indicate horizon-
tal pleiotropy (eTable 20 in the Supplement).
Bidirectional single-variable analyses showed the
genetic liability for MDD, but not ASRD, having effect size
estimates consistent with increased risk of use for all opioid
and nonopioid pain medications (opioids OR, 1.18; 95% CI,
1.08-1.30; P < .001; anilides OR, 1.20; 95% CI, 1.00-1.28;
P < .001; NSAIDs OR, 1.15; 95% CI, 1.09-1.22; P < .001; sali-
cylic acid/derivatives OR, 1.10; 95% CI, 1.03-1.17; P = .002)
(Table 3; eTables 15-18 in the Supplement). These estimates
were broadly consistent with estimates from the weighted
median and MR-Egger sensitivity analyses; the MR-Egger
estimates were substantially less precise. The MR-Egger
intercept analysis did not indicate horizontal pleiotropy.
The F statistics for the genetic instruments were consistent
with an absence of weak instrument bias.
Discussion
We evaluated potential bidirectional associations between the
genetic liability for prescription opioid and nonopioid pain
medication use and both MDD and ASRD and found genetic
evidence that prescription opioid use was associated with in-
creased MDD and ASRD risk, while strikingly, nonopioid an-
algesics had no direct association with the risk for MDD or
ASRD.
Opioid MDD MR estimates were consistent in magnitude
and direction across IVW, weighted median, and MR-Egger
analyses, with the MR-Egger estimate substantially less pre-
cise, as is typically expected in MR genetic association stud-
ies, and the MR Egger intercept terms, being close to zero, con-
sistent with absence of pleiotropy.47 Our findings extend
observational literature suggesting prescription opioid use in-
creases the risk for MDD,19-21 and unlike 2020 evidence for a
causal effect of ICD-defined OUD on MDD,48 our opioid use in-
strument only included prescription opioids and not heroin,
suggesting important neuropsychiatric implications, beyond
the risk for opioid misuse, and OUD, that may be considered
when prescribing opioids.
The underlying mechanisms of prescription opioids in the
pathophysiology of MDD remain to be elucidated, but poten-
tially include opioid-induced dysregulation of reward cir-
cuitry that results in reduced reward perception or pleasure
and relief generation49 or other physical medical dysregula-
tion (ie, endocrine and autonomic nervous system
abnormalities50) that potentially contributes to the physical
symptoms of MDD. Notably, it has been suggested that the
endogenous opioid system is directly involved in the regula-




SNVs OR (95% CI) P value
No. of
SNVs OR (95% CI) P value
Opioid use MV IVW 92 1.14 (1.04-1.25) .005 86 1.30 (1.08-1.56) .006
MV Egger 92 1.13 (1.02-1.26) .02 86 1.18 (0.95-1.46) .13
NSAID use MV IVW 92 0.98 (0.84-1.15) .81 86 1.37 (0.99-1.90) .06
MV Egger 92 0.97 (0.82-1.15) .72 86 1.23 (0.87-1.73) .24
Salicylic acid use MV IVW 92 0.99 (0.89-1.11) .88 86 0.96 (0.76-1.21) .70
MV Egger 92 0.98 (0.87-1.11) .76 86 0.84 (0.64-1.10) .21
Anilide use MV IVW 92 1.07 (0.89-1.29) .46 86 0.71 (0.49-1.03) .07
MV Egger 92 1.06 (0.87-1.28) .56 86 0.64 (0.43-0.94) .02
Abbreviations: ASRD, anxiety and stress-related disorder; GWAS, genome-wide
association studies; IVW, inverse variance weighted MR; MDD, major depression
or major depressive disorder (depending on study used in GWAS); MR,
mendelian randomization; MV IVW, multivariable inverse variance weighted;
MVMR, multivariable mendelian randomization; N SNV, number of SNVs; OR,
odds ratio; SNV, single-nucleotide variant.
a Results from outlier-corrected 2-sample multivariable MR analysis, 2
multivariable complementary methods reported; main analysis method:
estimates reported as OR of psychiatric outcome per unit increase in log odds
of pain medication use exposure, accounting for other pain medication uses.
b Instruments selected from opioid and nonopioid GWASs, selection threshold P
less than 5 × 10−6, pruned at linkage disequilibrium R2 less than 0.001 (10 000
kilobase pair window); outliers identified by MR PRESSO tool, removed; N
SNVs differs across outcomes depending on number of instrument SNVs
found in psychiatric outcome GWASs.
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tion of mood and the dysregulation of that system may factor
into depression and anxiety11,51,52; μ-opioid receptors (MOR)
are widely distributed within the brain, including regions in-
volved in emotion regulation,11 and κ-opioid receptors (KOR)
are expressed in the cortex, striatum, hippocampus, amyg-
dala, and thalamus,53 suggesting a role in reward, pain, and
emotion. Opioid receptor antagonism has also been shown to
attenuate ketamine’s antidepressant effects,54 and sube-
uphoric doses of partial opioid agonists have been shown to
improve MDD symptoms.11 However, while small opioid doses
may improve mood by activating MORs, prolonged opioid use
may saturate MORs and activate the KOR, which also modu-
late mood55,56 and are associated with depression54,57; in ro-
dents, KOR agonists increase anxiety while deficiencies in the
KOR system decrease anxiety.51 In humans, prolonged opioid
use (30 days or more), which may saturate the opioid recep-
tor system to affect mood,54 increased risk for developing treat-
ment-resistant depression by more than 25%, compared with
opioid use for less than 30 days.21 Elucidating the underlying
mechanisms of the opioid system dysregulation potentially
shared between MDD and OUD may be important to combat
these crises.11
Our bidirectional analyses, with genetic liability for pre-
scription opioid use as an outcome, point to genetic liability
for MDD but not ASRD as a possible causal risk factor of opi-
oid use in psychiatric populations. Depression severity has been
shown to be associated with increasing likelihood of misus-
ing opioid medications for nonpain symptoms and self-
increasing opioid dosage58 and up to 30% of long-term opi-
oid users who have MDD qualify for moderate-to-severe
OUD,15,59 suggesting that targeting opioid use prevention for
patients with MDD may help mitigate the US opioid
epidemic.1,10 Given more than half of individuals with OUD
have comorbid MDD,10 the increased use of opioids by indi-
viduals with MDD may be owing to self-medication of social
or emotional pain,11 suggesting that the development of thera-
peutic interventions with minimal risk targeted at endoge-
nous opioid dysregulation represents another important pre-
vention opportunity.11 In sum, our findings support
recommendations that caution is needed with prescribing in
settings of mood disorders in favor of nonopioid alternatives,
with screening for MDD prior to initiating opioid treatment.10
Further, our findings that the genetic liability for MDD in-
creased the risk of the genetic liability to take NSAIDs, ani-
lide, and salicylic acid and derivatives support the well-
known association between depression and physical pain;
comorbid depression and pain experience reduce physical,
mental, and social functioning when beyond either depres-
sion or pain.60 Further still, our findings that genetic liability
for NSAIDs use increased the risk for MDD and ASRD sup-
ports observational evidence suggesting NSAIDs have ad-
verse neural effects, including neuropsychiatric symptoms,61,62
although the association direction is opposite to reported RCTs
using NSAIDs as adjunct therapies for depression.63 The NSAID-
related adverse neuropsychiatric symptoms are most often re-
ported with indomethacin and selective cyclooxygenase-2 in-
hibitors, which may modulate neural processes and synaptic
signaling processes where cyclooxygenase-2 is localized.61
Strengths and Limitations
This innovative 2-sample MR study investigating the associa-
tion between genetic liability for opioid and other pain medi-
cation use and neuropsychiatric outcomes has several
strengths. We use summary genetic associations from the larg-
est available GWASs, important genetic analyses investigat-
ing small effect sizes; generally, larger sample sizes increase
measurement precision. We also use complementary 2-sample
MR methods for sensitivity analysis.64 The MVMR models are
a major strength, enabling us to account for potential con-
founding owing to chronic pain, and also to estimate the di-
rect association for genetic liability for prescription opioid use.
Relatedly, including nonopioid pain medications provided
Table 3. Single-Variable MR Results of Risk of MDD and ASRD on Risk of Prescription Opioid and Nonopioid Pain Medications Use a,b
Exposure Methods
Opioid use Salicylic acid use Anilide use NSAIDs use
No. of













































































Abbreviations: ASRD, anxiety and stress-related disorder; GWAS, genome-wide
association studies; IVW, inverse-variance weighted; MDD, major depression or
major depressive disorder (depending on study); MR, mendelian
randomization; MV, multivariable; N SNV, number of SNVs; NSAID, nonsteroidal
anti-inflammatory drug; OR, odds ratio; SNV, single-nucleotide variant; SVMR,
single-variable mendelian randomization.
a Results from 2-sample SVMR analysis; main analysis method: IVW is
boldfaced; outliers identified by MR PRESSO tool, removed; estimated
associations reported as OR of pain medication use per unit increase in log
odds of psychiatric exposure.
b Genetic instruments selected from MDD and ASRD GWASs, selection
threshold P less than 5 × 10−6, pruned at linkage disequilibrium R2 less than
0.001 (10 000 kilobase pair window); N SNV differs across outcomes
depending on number of genetic instruments found in outcome GWASs.
Prescription Opioid Use and Risk for Major Depressive Disorder Original Investigation Research
jamapsychiatry.com (Reprinted) JAMA Psychiatry Published online November 11, 2020 E7
Downloaded From: https://jamanetwork.com/ on 01/27/2021
additional context to the prescription opioid findings be-
cause none of the nonopioid pain medications retained a di-
rect association with our neuropsychiatric outcomes in MVMR
analyses. Finally, the list of prescribed prescription opioids
comprising our opioid variable excludes heroin and other il-
licit opioid substances, enabling us to evaluate the specific as-
sociation between the genetic liability for prescribed opioids
and MDD.
There are also limitations to this study. The pain medica-
tion use and psychiatric disorder SNV effect estimates were ob-
tained in mostly European studies, thus minimizing the pos-
sibility of population stratification bias and increasing the
plausibility of the 2-sample MR assumption that summary as-
sociations derived from comparable populations.39,65 We per-
formed sensitivity analyses to assess and minimize heteroge-
neity and pleiotropy. Nonetheless, we emphasize the
importance of triangulating multiple lines of experimental evi-
dence to strengthen causal inference.66
Regarding genetic instrument selection, following the ex-
ample of prior MR studies,67,68 we used a stringent selection
threshold (P < 5 × 10−6) for the pain medication use and ASRD
risk instruments to compensate for lack of SNVs with effect P
values less than conventional genome-wide significance
(P < 5 × 10−8). We also used stringent LD clumping thresholds
to ensure instrument independence. The biologic mecha-
nisms of the selected SNVs are unknown; however, sensitiv-
ity analyses failed to find evidence for horizontal pleiotropy.
Further, each pain medication phenotype was a binary vari-
able (use/nonuse), so we could not assess potential dose-
dependent changes in risk associated with prescription opi-
oid use. Also, the genetic variants for pain medication use may
be related to underlying disease, pain conditions, or even sub-
clinical levels of the traits that influence MDD risk,28 which may
affect results, although we note the association of the genetic
liability of opioid use found in single-variable MR persisted in
MVMR accounting for genetic liability for site-specific chronic
pain. Nonetheless, future genetic studies using detailed hos-
pital-based information about pain medication and includ-
ing negative control populations would possibly allow to fur-
ther strengthen causal inference. Finally, as has been noted
previously, the UKB cohorts may not represent the general UK
population,69 and analyses were limited to individuals of Eu-
ropean ancestry; caution is warranted before generalizing find-
ings to other populations.
Conclusions
We provide preliminary genetic evidence that prescription opi-
oid use increases MDD and ASRD risk, suggesting important
clinical consequences. We also find genetic evidence that MDD
is a potential causal risk factor for increased prescription opi-
oid use, which may help identify patient populations to aim
prevention strategies to curb the ongoing opioid epidemic.
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